We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
Jan 7, 2022 8:30 AM EST
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
SOUTH SAN FRANCISCO, Calif. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to 9 new employees, whose employment commenced in December 2021 , as
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN
SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present virtually at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
JI XING to Develop and Commercialize Novel Cardiac Myosin Activator in Patients with Heart Failure Cytokinetics to Receive $70 Million in Committed Capital ; Up to an Additional $330 Million in Potential Milestone Payments Plus Royalties Cytokinetics to Host Conference Call and Webcast Today at
